Inhibition of Src activity enhances the tumor-suppressive effect of the connexin 32 gene in Caki-1 renal cancer cells

Oncology Reports

Volumn 15, Issue 5, 2006, Pages 1359-1365

  Fujimoto, Eriko ^a,b   Sato, Hiromi ^a,b   Shirai, Sumiko ^a,c   Nagashima, Yoji ^c   Virgona, Nantiga ^d   Hagiwara, Kiyokazu ^a   Yamasaki, Hiroshi ^d   Negishi, Etsuko ^b   Ueno, Koichi ^b   Yano, Tomohiro ^a  

^a NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Connexin 32; Hypoxia; Renal cell carcinoma; Src; Tumor suppressor gene

Indexed keywords

4 AMINO 5 (4 METHYLPHENYL) 7 (TERT BUTYL)PYRAZOLO(3,4 D)PYRIMIDINE; 4-AMINO-5-(4-METHYLPHENYL)-7-(TERT-BUTYL)PYRAZOLO(3,4-D)PYRIMIDINE; CONNEXIN 32; ENZYME INHIBITOR; GAP JUNCTION PROTEIN; PROTEIN KINASE P60; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; CELL CYCLE; CELL HYPOXIA; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; GENETIC TRANSFECTION; GENETICS; HUMAN; KIDNEY CARCINOMA; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY;

ANIMALS; APOPTOSIS; CARCINOMA, RENAL CELL; CELL CYCLE; CELL HYPOXIA; CONNEXINS; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTO-ONCOGENE PROTEINS PP60(C-SRC); PYRAZOLES; PYRIMIDINES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 33744979530     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.5.1359     Document Type: Article

References (30)

1. Motzer RJ, Bander N and Nanus DM: Renal-cell carcinoma. N Engl J Med 335: 865-875, 1996.
2. Rabinovitch RA, Zelefsky MJ, Gaynor JJ and Fuks Z: Patterns of failure following surgical resection of renal cell carcinoma implications for adjuvant local and systematic therapy. J Clin Oncol 12: 206-212, 1994. (Pubitemid 24020641)
3. Neigrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T and Tursz T: Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338: 1272-1278, 1998. (Pubitemid 28216581)
4. Mesnil M and Yamasaki H: Cell-cell communication and growth control of normal and cancer cells: evidence and hypothesis. Mol Carcinog 7: 14-17, 1993. (Pubitemid 23061282)
5. Yano T, Hernandez-Blazqueze FJ, Omori Y and Yamasaki H: Reduction of malignant phenotype of HepG2 is associated with the expression of connexin 26 but not connexin 32. Carcinogenesis 22: 1593-1600, 2001. (Pubitemid 32952136)
6. Mesnil M: Connexin and cancer. Biol Cell 94: 493-500, 2002.
7. Yano T, Ito F, Satoh H, Hagiwara K, Nakazawa H, Toma H and Yamasaki H: Tumor-suppressive effect of connexin 32 in renal cell carcinoma from hemodialysis patients. Kidney Int 63: 381, 2003. (Pubitemid 35463946)
8. Yano T, Ito F, Kobayashi K, Yonezawa Y, Suzuki K, Asano R, Hagiwara K, Nakazawa H, Toma H and Yamasaki H: Hypermethylation of the CpG island of connexin 32: a candidate tumor suppressor gene in renal cell carcinomas from hemodialysis patients. Cancer Lett 208: 137-142, 2004. (Pubitemid 38624154)
9. Fujimoto E, Sato H, Shirai S, Nagashima Y, Fukumoto K, Hagiwara H, Negishi E, Ueno K, Omori Y, Yamasaki H, Hagiwara K and Yano T: Connexin 32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line. Oncogene 24: 3684-3690, 2005. (Pubitemid 40756238)
10. Brown MT and Cooper JA: Regulation, substrates and functions of src. Biochem Biophys Acta 1287: 121-149, 1996. (Pubitemid 26189191)
11. Frame MC: Src in cancer: deregulation and consequences for cell behavior. Biochim Biophys Acta 1602: 114-130, 2002.
12. Yonezawa Y, Nagashima Y, Sato H, Virgona N, Fukumoto K, Shirai S, Hagiwara H, Seki T, Ariga T, Senba H, Suzuki K, Asano R, Hagiwara K and Yano T: Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells. Mol Carcinog 43: 188-197, 2005. (Pubitemid 41134426)
13. Kumar NM and Gilula NB: Cloning and characterization of human and rat liver cDNAs coding for a gap junction protein. J Cell Biol 103: 767-776, 1986. (Pubitemid 17177326)
14. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA and Connelly PA: Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 271: 695-701, 1996.
15. Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal T, Varticovski L and Isner JM: Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 270: 31189-31195, 1995. (Pubitemid 26012206)
16. Ellis LM, Staley CA, Liu W, Fleming RY, Parikh NU, Bucana CD and Gallick GE: Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 273: 1052-1057, 1998. (Pubitemid 28049203)
17. Cartwright CA, Meisler AI and Eckhart W: Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci USA 87: 558-562, 1990.
18. Termuhlen PM, Curley SA, Talamonti MS, Saboorian MH and Gallick GE: Site-specific differences in pp60c-src activity in human colorectal metastases. J Surg Res 54: 293-298, 1993. (Pubitemid 23235765)
19. Bromberg JF, Wreszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: STAT3 as an oncogene. Cell 98: 295-303, 1999. (Pubitemid 29380565)
20. Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ and Jove R: Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 19: 5419-5422, 2000.
21. Catlett-Falcone R, Landowski TH, Oshino MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS and Jove R: Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115, 1999. (Pubitemid 29077388)
22. Sato H, Nagashima Y, Shirai S, Fukumoto K, Hagiwara H, Yamasaki H, Hagiwara K, Negishi E, Ueno K and Yano T: Combination effect of connexin32 gene function and chemotherapeutic agents against mestastatic renal cell carcinoma cells. Proc Am Assoc Cancer Res 46: 785, 2005.
23. Chao DT and Korsmeyer SJ: Bcl-2 family: regulators of cell death. Annu Rev Immunol 16: 395-419, 1998. (Pubitemid 28183370)
24. Harris AL: Hypoxia-A key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
25. Brown JM and Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447, 2004. (Pubitemid 38745529)
26. Hockel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276, 2001. (Pubitemid 32219813)
27. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS and Gallick GE: HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24: 3110-3120, 2005. (Pubitemid 40695080)
28. Simpson I, Rose B and Loweinstein WR: Size limit of molecule permeating the junctional membrane channels. Science 195: 294-296, 1977. (Pubitemid 8015334)
29. Krutovskikh VA, Piccoli C and Yamasaki H: Gap junction intercellular communication propagates cell death in cancerous cells. Oncogene 21: 1989-1999, 2002. (Pubitemid 34270887)
30. Lin JH, Weigel H, Cotrina, ML, Liu S, Bueno E, Hansen AJ, Hansen TW, Goldman S and Nedergard M: Gap-junction-mediated propagation and amplification of cell injury. Nat Neurosci 1: 494-500, 1998.